pharma2020_virtualrd_final2

pharma2020_virtualrd_final2 - Pharmaceuticals & Life...

Info iconThis preview shows pages 1–4. Sign up to view the full content.

View Full Document Right Arrow Icon
Pharma 2020: Virtual R&D Which path will you take? Pharmaceuticals & Life sciences
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Table of contents Table of contents Innovation essentials 1 Getting to know ourselves 4 Making research more predictive 6 Expediting development 9 Collaborating to bring treatments to the market 15 Imperatives for change 18 Acknowledgements 19 References 20 Contacts 21 Pharma 2020: Virtual R&D – Which path will you take? is the second in a series of papers published by PricewaterhouseCoopers exploring the future of the pharmaceutical industry. Published in June 2007, Pharma 2020: The vision – Which path will you take? highlighted a number of issues that will have a major bearing on the industry over the next 13 years and outlined the changes we believe will best help pharmaceutical companies realise the potential the future holds to enhance the value they provide to shareholders and society alike. This paper explores the opportunities to improve the R&D process. It proposes new technologies will enable the adoption of virtual R&D; and by operating in a more connected world, the industry in collaboration with researchers, governments, healthcare payers and providers, can address the changing needs of society more effectively.
Background image of page 2
Pharma 2020: Virtual R&D 1 Innovation essentials Pharma is at a pivotal point in its evolution. As we* indicated in “Pharma 2020: The vision” by PricewaterhouseCoopers, published in June 2007 1 , the social, demographic and economic milieu in which the industry operates is undergoing huge changes (see sidebar, Seven major trends reshaping the pharmaceutical marketplace ). These challenges have been compounded by the dearth of good new compounds in its pipeline. Seven major trends reshaping the pharmaceutical marketplace The pharmaceutical marketplace is changing dramatically, with huge ramifications for the industry as a whole. We have identified seven major socio-economic trends. The burden of chronic disease is soaring. The prevalence of chronic diseases like diabetes is growing everywhere. As greater longevity forces many countries to lift the retirement age, more people will still be working at the point at which these diseases start. The social and economic value of treatments for chronic diseases will rise accordingly, but Pharma will have to reduce its prices and rely on volume sales of such products because many countries will otherwise be unable to afford them. Healthcare policy-makers and payers are increasingly mandating what doctors can prescribe. As treatment protocols replace individual prescribing decisions, Pharma’s target audience is also becoming more consolidated and more powerful, with profound implications for its sales and marketing model. The industry will have to work much harder for its dollars, collaborate with healthcare payers and providers, and improve patient compliance.
Background image of page 3

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 4
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 07/08/2011 for the course BM 501 taught by Professor Kop during the Spring '11 term at Bloomsburg.

Page1 / 24

pharma2020_virtualrd_final2 - Pharmaceuticals & Life...

This preview shows document pages 1 - 4. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online